Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia
- PMID:32601581
- PMCID: PMC7323923
- DOI: 10.1007/s40473-019-00174-5
Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia
Abstract
Purpose of review: The objective of this article is to highlight the potential role of the galantamine-memantine combination as a novel antioxidant treatment for schizophrenia.
Recent findings: In addition to the well-known mechanisms of action of galantamine and memantine, these medications also have antioxidant activity. Furthermore, an interplay exists between oxidative stress, inflammation (redox-inflammatory hypothesis), and kynurenine pathway metabolites. Also, there is an interaction between brain-derived neurotrophic factor and oxidative stress in schizophrenia. Oxidative stress may be associated with positive, cognitive, and negative symptoms and impairments in white matter integrity in schizophrenia. The antipsychotic-galantamine-memantine combination may provide a novel strategy in schizophrenia to treat positive, cognitive, and negative symptoms.
Summary: A "single antioxidant" may be inadequate to counteract the complex cascade of oxidative stress. The galantamine-memantine combination as "double antioxidants" is promising. Hence, randomized controlled trials are warranted with the antipsychotic-galantamine-memantine combination with oxidative stress and antioxidant biomarkers in schizophrenia.
Keywords: Antioxidant; Clinical high risk; Galantamine; Memantine; Oxidative stress; Schizophrenia.
Conflict of interest statement
Conflict of Interest The authors declare that they have no conflict of interest.
Figures
Similar articles
- Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia.Koola MM.Koola MM.Mol Neuropsychiatry. 2018 Dec;4(3):134-148. doi: 10.1159/000494495. Epub 2018 Nov 19.Mol Neuropsychiatry. 2018.PMID:30643787Free PMC article.Review.
- Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity.Koola MM, Nikiforuk A, Pillai A, Parsaik AK.Koola MM, et al.J Geriatr Care Res. 2018;5(2):57-67.J Geriatr Care Res. 2018.PMID:30984874Free PMC article.
- Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.Koola MM.Koola MM.Prim Care Companion CNS Disord. 2018 Mar 1;20(2):17nr02235. doi: 10.4088/PCC.17nr02235.Prim Care Companion CNS Disord. 2018.PMID:29570959Review.
- Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.Koola MM, Buchanan RW, Pillai A, Aitchison KJ, Weinberger DR, Aaronson ST, Dickerson FB.Koola MM, et al.Schizophr Res. 2014 Aug;157(1-3):84-9. doi: 10.1016/j.schres.2014.04.037. Epub 2014 May 28.Schizophr Res. 2014.PMID:24878431Free PMC article.Review.
- Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.Koola MM.Koola MM.Schizophr Res Cogn. 2016 Jun;4:4-9. doi: 10.1016/j.scog.2016.02.001.Schizophr Res Cogn. 2016.PMID:27069875Free PMC article.
Cited by
- Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.Veselinović T, Neuner I.Veselinović T, et al.CNS Drugs. 2022 Aug;36(8):819-858. doi: 10.1007/s40263-022-00935-z. Epub 2022 Jul 13.CNS Drugs. 2022.PMID:35831706Free PMC article.Review.
- Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway.Tanaka M, Tóth F, Polyák H, Szabó Á, Mándi Y, Vécsei L.Tanaka M, et al.Biomedicines. 2021 Jun 25;9(7):734. doi: 10.3390/biomedicines9070734.Biomedicines. 2021.PMID:34202246Free PMC article.Review.
- A Meta-Analysis of Brain-Derived Neurotrophic Factor Effects on Brain Volume in Schizophrenia: Genotype and Serum Levels.Ahmed AO, Kramer S, Hofman N, Flynn J, Hansen M, Martin V, Pillai A, Buckley PF.Ahmed AO, et al.Neuropsychobiology. 2021;80(5):411-424. doi: 10.1159/000514126. Epub 2021 Mar 11.Neuropsychobiology. 2021.PMID:33706323Free PMC article.Review.
- Age of Onset Moderates the Association between Total Antioxidant Capacity and Cognitive Deficits in Patients with Drug-Naïve Schizophrenia.Li J, Li D, Guo J, Wang D, Zhang X.Li J, et al.Antioxidants (Basel). 2023 Jun 12;12(6):1259. doi: 10.3390/antiox12061259.Antioxidants (Basel). 2023.PMID:37371989Free PMC article.
- BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review.Nieto RR, Carrasco A, Corral S, Castillo R, Gaspar PA, Bustamante ML, Silva H.Nieto RR, et al.Front Psychiatry. 2021 Jun 16;12:662407. doi: 10.3389/fpsyt.2021.662407. eCollection 2021.Front Psychiatry. 2021.PMID:34220575Free PMC article.Review.
References
Hoskins RG. Oxygen metabolism in schizophrenia. Arch Neurol Psychiatr 1937;38(6):1261–70
This is presumably the first publication on oxygen metabolism in schizophrenia.
Hoffer A, Osmond H, Smythies J. Schizophrenia; a new approach. II. Result of a year’s research. J Ment Sci 1954;100(418):29–45
This is one of the first publications on oxidative stress in schizophrenia.
- Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996;55(1–2):45–54. - PubMed
- Ramchand CN, Davies JI, Tresman RL, Griffiths IC, Peet M. Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients. Prostaglandins Leukot Essent Fatty Acids 1996;55(1–2):27–31. - PubMed
- Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996;55(1– 2):33–43. - PubMed
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials